DMRA Damora Therapeutics, Inc.
Company Analysis
Latest News
π΄ Damora Therapeutics is trading 5% down today as Treasury yields climb
Damora Therapeutics is trading 5.12% down now at $30.78, with broader risk-off conditions the most likely explanation as Treasury yields resumed climbing and...
Damora Therapeutics Lost More Money Than Expected Building Its Blood-Cancer Bet β Can $540 Million in Cash Buy Enough Time?
Shares of Damora Therapeutics (DMRA) cratered 8.6% to $27.00 in pre-market trading after the clinical-stage biotech reported second-quarter results that left...
π΄ Damora Therapeutics is trading 8.6% down in pre-market after quarterly net loss widened to $31.2 million
Damora Therapeutics is trading at $27.00 (-8.6%) after second-quarter results reported on August 10, 2026. β’ Q2 EPS of -$0.39 beat the -$0.43 consensus...
Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Damora Therapeutics is expected to report zero revenue and a consensus EPS of -$0.38 for Q2 2026, with the current share price of $29.92 sitting significantly...
Damora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Damora Therapeutics is expected to report zero revenue and a consensus EPS loss of $0.38 for Q2 2026, with the stock currently trading at $29.50 compared to a...
π’ Damora Therapeutics is trading 5.4% up today amid broader market risk-on sentiment
Damora Therapeutics is trading 5.4% higher at $29.86 as a broader market rebound lifts equities despite a lack of company-specific catalysts. β’ The upward...
Damora Therapeutics Earns Buy Rating, Jefferies Sees 73% Upside in Blood Cancer
Jefferies initiated coverage of Damora Therapeutics (DMRA) on July 27, 2026. Analyst Akash Tewari issued a Buy rating for the stock. The firm set a price...
π’ Damora Therapeutics is trading 5.1% up today amid risk-on sentiment
Damora Therapeutics is trading 5.1% up at $30.30 today amid a broader market risk-on sentiment, as there are no clear company-specific catalysts for the...
Damora Therapeutics Slumps, Facing Incyteβs Faster and Easier Rival Drug
Damora Therapeutics (DMRA) shares declined on July 22, 2026. Reports indicate a competing blood disorder drug from Incyte will likely reach the market one...
π’ Damora Therapeutics is trading 5.3% up today after HC Wainwright reiterates Buy rating and $45 price target
Damora Therapeutics is trading 5.3% higher at $34.74 after HC Wainwright reiterated its Buy rating and $45 price target, highlighting significant upside...
π’ Damora Therapeutics is trading 10.2% up
Damora Therapeutics is trading at $34.68, up 10.2% from a comparison close of $31.48 during regular trading. This is a price-action follow-up, so a separate...
π’ Damora Therapeutics is trading 5.75% up today on pipeline milestones and strong cash runway
Damora Therapeutics is trading 5.75% up at $33.29 as traders refocus on the company's near-term blood-disorder pipeline milestones and strong cash runway. β’...
π’ Damora Therapeutics is trading 10.1% up
Damora Therapeutics is trading at $30.84, up 10.1% from a comparison close of $28.00 during regular trading. This is a price-action follow-up, so a separate...
π’ Damora Therapeutics is trading 5.3% up today, rebounding on improved risk sentiment
Damora Therapeutics is trading 5.3% up at $29.49, reversing last weekβs pullback amid improving risk sentiment following softer June CPI inflation. β’ The move...
π΄ Damora Therapeutics is trading 5.1% down today on profit-taking after a recent rally
Damora Therapeutics is trading 5.1% down today at $27.08 on profit-taking and price normalization following a volatile two-week rally. β’ The reversal comes...
π΄ Damora Therapeutics is trading 5.4% down today after reversing gains from its recent rally
Damora Therapeutics is trading at $29.11 (-5.43%) in a sharp move lower that appears to be a price-action reversal following a 10.8% rise in the prior...
π’ Damora Therapeutics is trading 10.8% up
Damora Therapeutics is trading at $30.50, up 10.8% from a comparison close of $27.53 during regular trading. This is a price-action follow-up, so a separate...
Damora Therapeutics Jumps 7.6% on Pipeline Hopes, but Can Investor Enthusiasm Survive Without Hard News?
Shares of Damora Therapeutics surged 7.6% to $29.62 on July 9, reclaiming nearly all of the prior session's 8.23% selloff β despite no new company...
π’ Damora Therapeutics is trading 7.6% up today on investor positioning ahead of pipeline milestones
Damora Therapeutics is trading 7.6% up at $29.62 on investor positioning ahead of pipeline milestones, rebounding from the previous session's 8.23% decline. β’...
π΄ DMRA extends move to 7.4% down
DMRA is trading at $27.77, down 7.4% versus the comparison close of $30.00 during regular trading. This is a price-movement alert; no separate company-specific...